AN2 Therapeutics, Inc. (ANTX)
Nasdaq · Healthcare · Biotechnology
$5.61−1.75%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $212M
- 52-week range
- $1.00 – $7.19
- 52-week change
- +346.09%
- EPS (trailing)
- −$1.05
Fiscal year to Dec 2025
- Net income
- −$35.2M
- Diluted EPS
- −$1.16
From the company’s annual report on SEC EDGAR.
About AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform. It has a license agreement with Anacor Pharmaceuticals, Inc.
Headquarters: Menlo Park, United States · 21 employees · an2therapeutics.com